The Physician Executive has his thoughts, but I think the reason is much simpler. Repackaging two cheap, generic medications into an expensive, brand-name pill is generally not a good business model for success.
Why did BiDil fail?
ADVERTISEMENT
ADVERTISEMENT
More in Uncategorized
Past Week
-
The silent crisis hurting pain patients and their doctors
-
How the CDC’s opioid rules created a crisis for chronic pain patients
-
How to build a culture where physicians feel valued [PODCAST]
-
From the other side of the table: a plea for empathy
-
Why vaccine access still fails America’s most vulnerable groups
-
ADHD isn’t one-size-fits-all: Why nuance in diagnosis matters
-
Past 6 Months
-
How trade wars could destroy the U.S. health care system
-
The hidden bias young female physicians face every day
-
How hospitals are quietly taking control of physicians
-
Cutting opioid use in half: a hospital’s pain management breakthrough
-
How to advocate for your transgender child’s health care
-
How the system hunts physicians who refuse to kneel
-
Recent Posts
-
Healers or criminals: the alarming trend of physician prosecution [PODCAST]
-
Teaching by humiliation is still crushing future doctors
-
A philosophical shift: the doctor’s journey into the role of patient
-
What happened to real care in health care?
-
When saving lives leads to losing your own
-
A surgeon’s startling ketamine experience [PODCAST]
-
Subscribe to KevinMD and never miss a story!
Get free updates delivered free to your inbox.
